Frankfurt (Germany): In July, Phialogics, a preclinical-stage biotechnology company dedicated to the development of innovative biologics to treat autoimmune disease, was founded in Frankfurt, Germany. The founding team, composed of experienced academic researchers and industry veterans, is excited to bring a new generation of immune-modulatory drugs to patients. Phialogics’ disruptive approach aims to maximize therapeutic impact while reducing side-effects in the treatment of autoimmune diseases.
Andreas Ernst, CEO/CSO of Phialogics comments: “After years or research & development, we are now ready to take the next step, create Phialogics and develop a range of drugs to address auto-immune disease. Thanks to Phialogics’ engineered lead molecules, we are convinced that our drugs will be of great benefit to patients suffering from auto-immune disease.”